The Incidence, Mortality, and Survival of Hepatocellular Carcinoma in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2000-2023 Database Analysis
Medical Research Archives · 2026
DOI: 10.18103/mra.2026.0720 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Research Archives, 2026. Verfasst von Vlad Zah und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Accounting for 80% of US primary liver malignancies, hepatocellular carcinoma (HCC) is frequently detected at advanced stages, which complicates disease management. HCC imposes substantial financial strains and healthcare disparities in real-world settings. Despite this heavy clinical and economic toll, population-level evidence regarding the updated US disease burden remains scarce.
Aims
To evaluate epidemiologic trends and disease burden of HCC in the US using the Surveillance, Epidemiology, and End Results (SEER) data released in April 2026.
Methods
Utilizing SEER*Stat software across 21 cancer registries, malignant HCC cases diagnosed between 2000 and 2023 were captured using the International Classification of Diseases for Oncology, 3rd Edition. Main outcome measures were crude incidence and mortality rates (per 100,000 population), alongside 1-year and 5-year observed survival. Annual changes and trends in incidence and mortality were quantified as annual percent changes (APCs) derived through weighted least-squares regression.
Results
The study cohort comprised 240,253 patients, with non-specified HCC representing 97.8% of cases. Demographically, the population was predominantly male (75.9%), elderly (50.4%), Non-Hispanic White (48.8%), metropolitan residents (89.7%), and in the $65,000 – $90,000 county-level median annual household income (AHI) tier (50.4%). Overall HCC incidence was 7.027. Peak incidence rates were observed in non-specified HCC subtype (6.873), males (10.794), elderly individuals (27.219), Non-Hispanic Asian/Pacific Islanders (10.238), metropolitan area residents (7.050), and the $40,000 – $65,000 AHI stratum (7.654). Significant increases in incidence trends were captured for non-specified HCC (APC=3.238, p
Zitieren
APA
Zah, V., Stanicic, F., & Grbic, D. (2026). The Incidence, Mortality, and Survival of Hepatocellular Carcinoma in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2000-2023 Database Analysis. Medical Research Archives. https://doi.org/10.18103/mra.2026.0720
Vancouver
Zah V, Stanicic F, Grbic D. The Incidence, Mortality, and Survival of Hepatocellular Carcinoma in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2000-2023 Database Analysis. Medical Research Archives. 2026. doi:10.18103/mra.2026.0720
BibTeX
@article{Zah2026,
author = {Zah, Vlad and Stanicic, Filip and Grbic, Dimitrije},
title = {The Incidence, Mortality, and Survival of Hepatocellular Carcinoma in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2000-2023 Database Analysis},
journal = {Medical Research Archives},
year = {2026},
doi = {10.18103/mra.2026.0720}
}
EUVIMED